These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7675688)

  • 1. Liposomal MTP-PE: a promising new biologic response modifier.
    Gano JB; Kleinerman ES
    Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal MTP-PE.
    Gano JB; Kleinerman ES
    J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
    [No Abstract]   [Full Text] [Related]  

  • 3. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status.
    Frost H
    Biotherapy; 1992; 4(3):199-204. PubMed ID: 1599803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
    Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H
    Eur J Cancer; 1994; 30A(6):842-3. PubMed ID: 7917546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
    Kleinerman ES; Jaffe N
    Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
    [No Abstract]   [Full Text] [Related]  

  • 14. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
    Ando K; Mori K; Corradini N; Redini F; Heymann D
    Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
    Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
    Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
    Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.
    Fedorocko P
    Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
    Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
    J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.